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www.rsc.org/locMicrofluidic assembly of multistage porous
silicon–lipid vesicles for controlled drug release†
Bárbara Herranz-Blanco,a Laura R. Arriaga,b Ermei Mäkilä,ac Alexandra Correia,a
Neha Shrestha,a Sabiruddin Mirza,ab David A. Weitz,b Jarno Salonen,c
Jouni Hirvonena and Hélder A. Santos*aA reliable microfluidic platform for the generation of stable and
monodisperse multistage drug delivery systems is reported. A
glass-capillary flow-focusing droplet generation device was used to
encapsulate thermally hydrocarbonized porous silicon (PSi) micro-
particles into the aqueous cores of double emulsion drops, yielding
the formation of a multistage PSi–lipid vesicle. This composite
system enables a large loading capacity for hydrophobic drugs.
Microfluidic technologies are becoming widely used methods
for many applications ranging from material science1–3 to
biology.4 Particularly relevant for drug delivery applications
is the controlled production of capsules5–7 or vesicles8,9 using
microfluidic methods; these not only provide a higher
encapsulation efficiency10–12 than conventional production
techniques, but also endow the delivery vehicles with extremely
uniform sizes3 and very controlled chemical compositions.
Widely used templates for capsules or vesicles are water-in-oil-
in-water (W/O/W) double emulsion drops: their aqueous cores
provide an ideal environment for the dissolution of hydrophilic
drugs, whereas their oil shells can be loaded with hydrophobic
molecules.13 After careful removal of the oil from the emulsion
shells, double emulsion drops turn into capsules or vesicles,
and their membranes protect the encapsulated material from
the external environment.14
Due to their high biocompatibility, lipid vesicles are long-
lasting recognized as promising drug delivery vehicles.15 If
prepared using microfluidic technologies,16 they can efficientlyencapsulate large amounts of drugs within their aqueous cores,
particularly hydrophilic drugs.17 Unfortunately, due to the
ultrathin nature of the lipid bilayer, the loading capacity of lipid
vesicles for hydrophobic drugs is rather limited.14 Porous silicon
(PSi) particles, which are also highly biocompatible delivery
vehicles and widely studied for biomedical applications,18–25
can overcome the limited hydrophobic loading capacity of the
lipid vesicles. With typical pore sizes ranging from 2 to 50 nm,
drug molecules confined within the mesopores maintain an
amorphous conformation, avoiding extensive crystallization of
the drugs, thereby leading to an increase in the drug dissolu-
tion rates.18,21,26–28 However, PSi microparticles typically show a
much faster release of their cargo,29,30 which may cause a pre-
mature degradation of drugs in the body and a decrease in their
therapeutic effect. The development of a new delivery platform
that preserves the high biocompatibility of the lipid vesicles
and PSi microparticles, provides a high loading capacity for
both hydrophilic and hydrophobic drugs, and allows a sustained
release of cargo, is therefore highly desired.1,3,31–35
Herein, we propose the combination of lipid vesicles with
PSi microparticles as a multistage drug delivery system. Using a
glass-capillary flow-focusing droplet generation device,10,36 ther-
mally hydrocarbonized PSi microparticles (THCPSiMPs)19,23,30,37
were encapsulated within the aqueous cores of water-in-oil-in-
water (W/O/W) double emulsion drops with ultrathin shells.
Dewetting of the oil from the shell of the double emulsions
induced the formation of a lipid bilayer.10 The presence of
THCPSiMPs within the aqueous cores of these lipid vesicles
not only provided the vesicles with higher loading capacity for
hydrophobic drugs, as a result of the high porosity of the PSi
microparticles, but also their synergistic effect endowed the
vehicle with a sustained drug delivery capacity.
To fabricate lipid-stabilized double emulsion drops with
ultrathin shells and simultaneously encapsulate THCPSiMPs
within their cores, we used a glass-capillary microfluidic device
that consisted of two tapered cylindrical capillaries with an
outer diameter of 1 mm, carefully sanded to a tip diameter of, 2014, 14, 1083–1086 | 1083































































































View Article Online80 and 120 μm for injection and collection, respectively, and
inserted into the opposite ends of a square capillary with an
outer diameter of 1 mm, as illustrated schematically in
Fig. 1a. An additional capillary inserted into the injection
capillary allowed both, the inner water and middle oil phases,
to co-flow within the injection capillary. The injection capil-
lary was hydrophobic; this favored the contact of the middle
oil phase with its wall. Large plug-like water drops containing
the THCPSiMPs were thus formed within the injection capil-
lary and broken-up at the tip into double emulsion drops
stabilized by the thin layer of oil that was wetting the capillary
wall (Fig. 1a). The collection capillary was hydrophilic; this
prevented the wetting of the oil shell of the emulsion on the
wall of the collection capillary.
As the inner water phase, we used an aqueous suspension
of THCPSiMPs with typical particle sizes of ca. 15 μm. To
facilitate the dispersion of the THCPSiMPs, they were first
wetted with ethanol and later suspended in an aqueous solu-
tion that contained 8 wt-% polyethylene glycol (PEG, 6 kDa)
and 2 wt-% polyvinyl alcohol (PVA, 13–23 kDa) at a final con-
centration of 3 mg mL−1. The suspension was sonicated and
poured into a syringe together with a magnetic stirrer allowing
vigorous shaking of the suspension, thereby avoiding micro-
particle aggregation and sedimentation during the injection of
the suspension within the microfluidic chip. Importantly, our
microfluidic approach provides a hundred percent encapsula-
tion efficiency as all the particles in the inner water phase
ended-up in the cores of the double emulsions as shown in
Fig. 1b. The middle oil phase contained 4.6 mg mL−1 of
1,2-dioleyl-sn-glycero-3-phosphocholine (DOPC, Avanti) dissolved
in a mixture of chloroform and hexane at a volume ratio of
1 : 1.8, eventually containing 0.25 mole-% of 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(DHPE-Rh, Molecular Probes) to fluorescently label the lipid
bilayer. The outer aqueous phase consisted of a 10 wt-% PVA
(13–23 kDa) aqueous solution.
The double emulsion droplets were collected in an aque-
ous solution of sucrose with the same osmolarity as the inner1084 | Lab Chip, 2014, 14, 1083–1086
Fig. 1 (a) Schematic illustration of the microfluidic device used to
fabricate water-in-oil-in-water (W/O/W) double emulsion drops with
ultrathin shells and PSi microparticles within their cores. (b) Optical
microscope image of a typical production at flow rates of the inner, middle
and outer phases which are 700, 700, and 5000 μL h−1, respectively.water phase (100 mOsm L−1); this avoided any osmotic stress
that may induce destabilization of the double emulsion drop-
lets. Under these conditions, the chloroform in the middle
oil phase easily evaporated from the shell of the double emul-
sions, thereby increasing the ratio of hexane (which is a poor
solvent for the lipids) within the oil shell of the double emul-
sion. This reduction in solvent quality induces an attraction
between the two monolayers of lipids at the oil/water inter-
faces of the double emulsions, which leads to the dewetting
of the hexane from the inner cores of the double emulsion
droplets; this ultimately results in the formation of the lipid
bilayer. The dewetting process occurs in about a couple of
minutes.10 The small amount of residual solvent present in
the vesicle after dewetting remains concentrated in a very small
region of the bilayer, allowing the bilayer to behave similarly
to vesicles produced by conventional approaches.10 Moreover,
the residual solvent evaporates further in the next days.
The resultant THCPSiMPs–lipid vesicle system had a mean
diameter of 114 ± 8.4 μm, as shown in the optical microscope
image in Fig. 2a. Each delivery vehicle consisted of a lipid
bilayer, which appears fluorescently labeled in the micro-
scope image shown in Fig. 2b, encapsulating the THCPSiMPs
within its aqueous core. A detailed scanning electron micro-
scope (SEM) image of a THCPSiMP such as those within the
vesicles, is shown in Fig. 2c. The residual oil after the
dewetting process is also visible by optical microscopy as
pointed out by the white region in Fig. 2b.
To test the potential of THCPSiMPs–lipid vesicles for drug
delivery applications, the THCPSiMPs were loaded with a
model drug, piroxicam. This drug belongs to the Biopharma-
ceutical Classification System class II, i.e. it is highly hydropho-
bic, poorly water-soluble and highly permeable across
biological membranes. To load piroxicam, the THCPSiMPs
were stirred in an acetone solution of piroxicam at 15 mg mL−1
for 2 h. Then, the suspension was centrifuged at 11300 × g
for 4 min and the pellet was washed 3 times with 0.5 mL of
MilliQ-water; water allows the removal of the excess piroxicam
from the surface of the particles, while avoiding a premature
release of the drugs from the pores. Finally, the loadedThis journal is © The Royal Society of Chemistry 2014
Fig. 2 (a) Optical microscope image showing a suspension of
THCPSiMPs–lipid vesicles in an aqueous solution of sucrose. Note that
since the lipid vesicles are in an aqueous suspension, there is more than
one focal level, and thus, only few droplets are focused at a time in the
picture. (b) Detailed optical microscope image of one of the vesicles.
A confocal fluorescence microscope image is overlayed to highlight
the lipid bilayer (in red). An oil pocket (white region) is still visible in the
micrograph. The vesicle stably encapsulates the THCPSiMPs as pointed
out by the blue region. (c) Detailed SEM of a typical THCPSiMP such as
those encapsulated within the lipid vesicles.
Fig. 4 Cell viability of intestinal HT-29 cancer cells after 3 h incuba-
tion with different concentrations (mg mL−1) of the bare THCPSi and
THCPSi–lipid vesicle microparticles assessed by a luminescence-based
assay. All experiments were conducted at 37 °C. Errors bars represent
the mean ± SD (n = 4). After removing the medium and washing the
wells twice with fresh 1× Hanks Balanced Salt Solution pH 7.4 (HBSS),
the samples were added to the wells and incubated for 3 h. For posi-
tive and negative controls, HBSS (pH 7.4; 100% cell viability) and triton
X-100 (<1% cell viability) were used. Statistical analysis was made by a
one-way analysis of variance (ANOVA), followed by a Dunnett's multi-
ple comparison test to analyze the data using GraphPad Prism v. 5.01
(GraphPad Software). The level of significance was set at probability of
*p < 0.05.































































































View Article Onlinemicroparticles were suspended into the inner water phase and
the production proceeded as described previously.
The drug release tests were performed by introducing the
resultant THCPSiMPs–lipid vesicles in a dialysis bag, immersed
into a buffer solution. We estimate that the number of
THCPSiMPs–lipid vesicles loaded in each dialysis bag is
approximately 90000, and each droplet contains a THCPSiMP
average mass of 0.0023 μg. The solution was placed in an
orbital incubator shaker at 37 °C and 45 rpm. Ten milliliters of
two saline phosphate buffer solutions, with different pH values
of 7.4 and 6, were used as the release media. Sample aliquots
of 200 μL were taken at different time points, and the same vol-
ume of a pre-warmed fresh release medium was immediately
replaced to keep constant the dissolution volume. The concen-
tration of piroxicam in the samples was analyzed by spectro-
photometry at a maximum absorbance wavelength of 333 nm
(NanoDrop, Thermo Scientific) and the results are shown in
Fig. 3. The drug (piroxicam) loading degree in the system was
19%. THCPSiMPs–lipid vesicles showed sustained release com-
pared to the bare THCPSiMPs. Moreover, while at pH 6 the
whole payload was released after 3 h, at pH 7.4 the drug
release was completed only after 6 h. These differences could
be due to the heterogeneous stability behavior of the lipid
bilayer towards different pH values. Although no morphological
changes were observed on the vesicles over time (ESI 1†),
breakage of vesicles was significant after approximately 4 h;
this explains the faster release observed after 200 min in Fig. 3.
In order to evaluate the cell viability of the particles,
mucus-secreting intestinal HT-29 (5.0 × 105 cells per well)29,30
cells were selected and the cells were cultured as described in the
ESI 2.† Briefly, a suspension of cells in Dulbecco's modified
Eagle medium was seeded into 96-well plates (100 μL per well,
Perkin Elmer Inc.) and allowed to attach overnight. The
THCPSiMPs and THCPSiMPs−lipid vesicles suspensions at
concentrations of 0.05–0.5 mg mL−1 were added into the wells
(100 μL per well). After 3 h incubation, the viability was assayed
with CellTiter-Glo (Promega Corporation) using a Varioskan
Flash fluorometer (Thermo Fisher Scientific).18–20,24–26,28–30This journal is © The Royal Society of Chemistry 2014
Fig. 3 Piroxicam release profile from THCPSiMPs, in black, and from
THCPSiMPs–lipid vesicles, in grey, in saline phosphate buffer at pH values
of 7.4 and 6, and 37 °C. Each experiment was performed in triplicate and
the vertical lines represent the standard deviation of each value (n = 3).As a result of the micrometric size of these microvehicles,
they are envisaged to be applied for oral drug delivery, and
thus, we evaluated their cytocompatibility with gastrointesti-
nal tract-related HT-29 cancer cell line (Fig. 4). In general,
and as expected,29,30 we observed a decrease in the cell viabil-
ity as the concentration of the particles increased. There were
no statistically significant differences (p < 0.05) in cell viability
between the bare THCPSiMPs and THCPSiMPs–lipid vesicles,
which demonstrates the cytocompatibility of both systems in
mucus-secreting intestinal HT-29 cells.
Conclusions
In conclusion, we have successfully produced a multistage
drug delivery system consisting of THCPSiMPs, with high
drug loading capacity, embedded within the aqueous core of
lipid vesicles. The microfluidic technology made possible the
production of THCPSiMPs–lipid vesicles in a highly reliable,
reproducible, and efficient manner. The delivery system was
characterized by optical microscopy and the drug release pro-
files were obtained at different pH values. The results showed
that the encapsulation of the THCPSiMPs within lipid vesi-
cles with a mean diameter of 114 μm is highly efficient and
stable. The drug loading degree of the system was 19%, and
the encapsulated drug showed a sustained release from the
THCPSiMPs–lipid vesicles compared to the bare THCPSiMPs,
particularly at pH 7.4, at which the whole payload was released
only after 6 h. Due to its potential biocompatibility, production reli-
ability, large loading capacity for hydrophobic drugs, and sustained
drug delivery capacity, we propose the THCPSiMPs–lipid vesicleLab Chip, 2014, 14, 1083–1086 | 1085































































































View Article Onlinecomposite as a promising drug delivery system for multiple bio-
medical applications.
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